%0 Journal Article
%A Majem, Margarita
%A Cobo, Manuel
%A Isla, Dolores
%A Marquez-Medina, Diego
%A Rodriguez-Abreu, Delvys
%A Casal-Rubio, Joaquín
%A Bueno, Teresa Moran
%A Bernabé-Caro, Reyes
%A Parente, Diego Pérez
%A Ruiz-Gracia, Pedro
%A Arroyo, Marta Marina
%A Paz-Ares, Luis
%T PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
%D 2021
%@ 2077-0383
%U http://hdl.handle.net/10668/17524
%X Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line anti-PD-(L)1 monotherapy in advanced NSCLC patients with high PD-L1 expression (≥50%) compared to platinum-based chemotherapy. We also evaluated efficacy outcomes according to tumor mutational burden (TMB). To that end, we conducted a systematic review. Six clinical trials with 2111 patients were included. In head-to-head comparisons, immunotherapy showed a significant improvement in progression-free survival (PFS: HRpooled = 0.69, 95% CI: 0.52-0.90, p = 0.007), overall survival (OS: HRpooled = 0.69, 95% CI: 0.61-0.78; p
%K PD-(L)1 inhibitors
%K efficacy
%K first-line treatment
%K immunotherapy
%K network meta-analysis
%K non-small cell lung cancer
%~